Precision biosciences stock.

Discover historical prices for DTIL stock on Yahoo Finance. View daily, weekly or monthly format back to when Precision BioSciences, Inc. stock was issued.

Precision biosciences stock. Things To Know About Precision biosciences stock.

Jun 21, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately ... At the core of Precision Biosciences’ groundbreaking research is the ARCUS genome editing technology. This cutting-edge technology possesses unparalleled precision and versatility, enabling scientists to insert, delete, or repair disease-causing DNA in a wide range of genetic disorders. With the potential to revolutionize the field of genetic ...Complete Precision Biosciences Inc. stock information by Barron's. View real-time DTIL stock price and news, along with industry-best analysis.DTIL Precision BioSciences Inc Form 8-K - Current report. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).Stock Quote. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High.

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary …

precisionbiosciences .com. Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. [3] Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform. [4] Precision BioSciences (DTIL) JonesTrading analyst Soumit Roy reiterated a Buy rating on Precision BioSciences today and set a price target of $4.00. The company’s shares closed last Wednesday at ...

precisionbiosciences .com. Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. [3] Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform. [4]Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Precision BioSciences (DTIL – Research Report). The associated price target is $3.00. Patrick Trucchio has given ...Precision Biosciences Inc. Watch list NEW Set a price target alert Open Last Updated: Dec 1, 2023 9:53 a.m. EST Real time quote $ 0.3645 0.0094 2.65% Previous Close $0.3551 Advanced Charting... Nov 20, 2020 · Under the terms of the agreement, Precision will receive an upfront cash payment of $100 million, as well as an equity investment by Lilly of $35 million in Precision's common stock. Precision is also eligible to receive up to $420 million in potential development and commercialization milestones per product, as well as tiered royalties ranging ... DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its …

7 thg 11, 2023 ... DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ...

View Precision BioSciences, Inc DTIL investment & stock information. Get the latest Precision BioSciences, Inc DTIL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Complete Precision Biosciences Inc. stock information by Barron's. View real-time DTIL stock price and news, along with industry-best analysis.Get the latest information on Precision BioSciences Inc (DTIL), a biotechnology company that develops and commercializes genomic tests for cancer and other diseases. …Precision BioSciences, Inc. Common Stock (DTIL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ...Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?Nov 6, 2023 · As of November 3, 2023, shares of Precision BioSciences were trading at $0.4256. Over the last 52-week period, the stock has experienced a decline of 68.38%. According to TipRanks, the average price target for DTIL is $2.58, with a high forecast of $4.00 and a low forecast of $1.00. In conclusion, investors will be closely monitoring Precision ...

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 24, 2023, Precision BioSciences, Inc. (the "Company") received a letter (the "Nasdaq Staff Deficiency Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, …Track Precision Biosciences Inc (DTIL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsPrecision BioSciences, Inc. : Forcasts, revenue, earnings, analysts expectations, ratios for Precision BioSciences, Inc. Stock | DTIL | US74019P1084Nov 14, 2019 · Shares of Precision BioSciences (DTIL 0.23%) ... As of 1:40 p.m. EST, the stock had settled to a 16.9% gain. The gene-editing stock is up 70% since the beginning of November. DTIL's stock price has decreased by -71.36% in the past year and price targets may not have had time to catch up. Stock Price Forecast According to 3 stock analysts, the average 12-month stock price forecast for DTIL stock stock is $3.00, which predicts an increase of 607.88%.Detailed statistics for Precision BioSciences, Inc. (DTIL) stock, including valuation metrics, financial numbers, share information and more. Skip to main content. Log In Free Trial. Home. Stocks. ... Precision BioSciences, Inc. (DTIL) NASDAQ: DTIL · IEX Real-Time Price · USD. Add to Watchlist 0.420-0.028 (-6.32%) At close: Nov 21, 2023, …DURHAM, N.C., November 07, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in ...

DURHAM, N.C.--(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of …28 thg 3, 2019 ... Precision Biosciences, the gene-editing startup, started trading on the Nasdaq stock exchange today after raising a $126.4 million IPO ...

Precision BioSciences, Inc. (Nasdaq: DTIL) will present at Hep-DART 2023 in Los Cabos, Mexico, showcasing their PBGENE-HBV Program for gene editing ...Dec 21, 2021 · DURHAM, N.C.--(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of investors led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary ... Jul 24, 2023 · Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Find out why I rate DTIL stock a Buy. HC Wainwright Adjusts Price Target on Precision BioSciences to $3 From $5, Keeps Buy Rating. Aug. 17. MT. BMO Capital Downgrades Precision BioSciences to Market Perform From Outperform, Adjusts Price Target to $4 From $7. Mar. 14. MT. Goldman Sachs Adjusts Price Target on Precision BioSciences to $1 From $2, Maintains Neutral Rating. Nov. 10. MT.DURHAM, N.C.--(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of investors led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary ...DURHAM - Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and... | March 29, 2023

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.

Precision Biosciences (NASDAQ:DTIL) is a biotech company with a proprietary gene-editing platform ... then I would expect the stock price to be below current price and no higher than $10, due to ...

28 thg 3, 2019 ... Precision Biosciences, the gene-editing startup, started trading on the Nasdaq stock exchange today after raising a $126.4 million IPO ...Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to ...Weighted average shares of common stock outstanding were approximately 110.8 million for the quarter ended September 30, 2022, as compared to approximately 59.7 million for the quarter ended September 30, 2021. ... Precision BioSciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per …Nov 30, 2023 · The stock of Precision Biosciences Inc (NASDAQ: DTIL) has decreased by -9.31 when compared to last closing price of 0.41.Despite this, the company has seen a loss of -11.84% in its stock price over the last five trading days. Business Wire reported 2023-10-23 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing […] Precision BioSciences to Present at Upcoming Sidoti Conference. DURHAM, N.C., November 10, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and …DURHAM, N.C.--(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of …Precision BioSciences (NASDAQ:DTIL), a biotechnology firm focusing on gene editing, announced that on November 21, the company's Compensation Committee authorized an inducement stock option for a ...Get a real-time Precision BioSciences, Inc. (DTIL) stock price quote with breaking news, financials, statistics, charts and more.precisionbiosciences .com. Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. [3] Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform. [4]

The Investor Relations website contains information about Precision BioSciences's business for stockholders, potential investors, and financial analysts. Precision BioSciences Conference Call and Webcast Information. Precision's management team will host a conference call and webcast tomorrow, June 22, ... risks related to ownership of our common stock and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly …Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update. August 4, 2023 at 7:15 AM EDT. ... Weighted average shares of common stock outstanding were approximately 114.1 million for the quarter ended June 30, 2023, as compared to approximately 68.0 million for the quarter ended June 30, 2022.Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee …Instagram:https://instagram. eaton vance stocknewer quarters worth moneycan you buy otc on webullfree demo account for forex trading Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ... new construction toll brothersnysearca slv compare Precision BioSciences Inc (DTIL) Stock Surges on Promising Performance and Consensus Buy Rating. On July 6, 2023, Precision BioSciences Inc (DTIL) stock experienced a significant increase in its price. The stock had a median target price of $5.00, with a high estimate of $17.00 and a low estimate of $1.00, as projected by six analysts … fidelity total bond The latest price target for Precision BioSciences ( NASDAQ: DTIL) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 3.00 expecting DTIL to ...Precision BioSciences, Inc. Common Stock (DTIL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Stifel Nicolaus Adjusts Precision BioSciences Price Target to $9 From $11, Maintains Buy Rating. Goldman Sachs Adjusts Precision BioSciences' Price Target to $2 From $3, Keeps Neutral Rating. More news. Press releases Precision BioSciences, Inc. Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update.